.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
QuintilesIMS
Teva
Johnson and Johnson
Baxter
Citi
UBS
Mallinckrodt
Chubb
Federal Trade Commission

Generated: July 20, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021845

« Back to Dashboard
NDA 021845 describes REVATIO, which is a drug marketed by Pfizer and is included in three NDAs. It is available from six suppliers. Additional details are available on the REVATIO profile page.

The generic ingredient in REVATIO is sildenafil citrate. There are twenty drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

Summary for NDA: 021845

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 021845

Suppliers and Packaging for NDA: 021845

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
REVATIO
sildenafil citrate
TABLET;ORAL 021845 NDA Pfizer Laboratories Div Pfizer Inc 0069-4190 0069-4190-68 90 TABLET, FILM COATED in 1 BOTTLE (0069-4190-68)
REVATIO
sildenafil citrate
TABLET;ORAL 021845 NDA AUTHORIZED GENERIC KAISER FOUNDATION HOSPITALS 0179-0160 0179-0160-08 8 TABLET, FILM COATED in 1 BOTTLE (0179-0160-08)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 20MG BASE
Approval Date:Jun 3, 2005TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Jan 31, 2017
Regulatory Exclusivity Use:INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY
Regulatory Exclusivity Expiration:Jan 31, 2017
Regulatory Exclusivity Use:NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS

Expired Orange Book Patents for NDA: 021845

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer
REVATIO
sildenafil citrate
TABLET;ORAL021845-001Jun 3, 20055,250,534*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Dow
Moodys
Cipla
Argus Health
Boehringer Ingelheim
Covington
Fuji
Cantor Fitzgerald
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot